Subsidiary & Affiliate News

Date Title  
Toggle Summary OncoCyte to be Added to the Russell 2000®, 3000® and Microcap Indexes
ALAMEDA, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective
Toggle Summary OncoCyte Announces Chief Executive Officer Transition
Appoints diagnostic industry veteran and current Board member  Ronald Andrews, Jr. as Chief Executive Officer Outgoing CEO William Annett to serve as an advisor to the Company Company to host conference call and webcast today, June 6 , at 8:30am EDT ALAMEDA, Calif.
Toggle Summary OncoCyte Announces Participation at the 2019 BIO International Convention
Company presentation scheduled for Wednesday, June 5 at 10:45am EDT   ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that Chief Executive Officer William
Toggle Summary OncoCyte Strengthens Senior Management Team With Two New Hires
Padma Sundar Appointed Senior Vice President, Marketing and Market Access Dr. Kim Dickinson Appointed Vice President, Clinical Operations ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection
Toggle Summary OncoCyte Presents Positive Results from R&D Validation Study of DetermaVu™ at the American Thoracic Society 2019 International Conference
Results were achieved using blood gene expression biomarkers alone and without the use of clinical parameters Company remains on-track to make DetermaVu™ commercially available in 2H 2019 ALAMEDA, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Toggle Summary OncoCyte Provides Corporate Update and Reports First Quarter 2019 Financial Results
Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Toggle Summary OncoCyte to Report First Quarter 2019 Financial Results on Tuesday, May 14
Company to host conference call and webcast at 4:30pm ET ALAMEDA, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results
Toggle Summary OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
  On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today reported
Toggle Summary OncoCyte to Present Late Breaking Abstract at the American Thoracic Society 2019 International Conference
Poster presentation and discussion to detail compelling results from R&D Validation study of the Company’s DetermaVu™ liquid biopsy test for the early detection of lung cancer ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel,
Toggle Summary OncoCyte to Report Fourth Quarter and Full-Year 2018 Financial Results on Monday, April 1, 2019
ALAMEDA, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31,
Toggle Summary OncoCyte Corporation to Present at Cowen and Company 39th Annual Health Care Conference in Boston
ALAMEDA, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , CEO of OncoCyte Corporation , will be presenting at the Cowen and Company 39 th Annual
Toggle Summary OncoCyte Announces Initiation of Analytical Validation Study
Company remains on-track for commercial availability of DetermaVu™ Lung in 2H 2019 ALAMEDA, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the
Toggle Summary OncoCyte Announces Closing of Public Offering of Common Stock
ALAMEDA, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering.
Toggle Summary OncoCyte Announces Pricing of Public Offering of Common Stock
ALAMEDA, Calif. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common
Toggle Summary OncoCyte Announces Proposed Public Offering of Common Stock
ALAMEDA, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten
Toggle Summary OncoCyte Announces Successful Results of DetermaVu™ R&D Validation Study
Results show 90% sensitivity and 75% specificity, demonstrating best-in-class performance On track for commercial availability of  DetermaVu™ Lung in 2H 2019 Results suggest the potential to address a U.S. market opportunity of $4.7 billion Unique immune system interrogation approach may have
Toggle Summary OncoCyte Schedules Announcement and Conference Call to Discuss Results from Key R&D Validation Study of DetermaVu™
Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET ALAMEDA, Calif , Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today scheduled an announcement and conference call to
Toggle Summary Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
FREMONT, Calif. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
Toggle Summary AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels
Toggle Summary OncoCyte Announces Transition to Ion Torrent Next-Generation Sequencing Platform
Ion GeneStudio™ S5 Demonstrates Generation of Consistent and Reproducible Results in Lung Cancer Studies ALAMEDA, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced its
Toggle Summary AgeX Therapeutics to Present at Biotech Showcase 2019
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at  Biotech Showcase , to be held January 7-9, 2019 in San